Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Wilson, Andrew J ^a   Barham, Whitney ^b   Saskowski, Jeanette ^a   Tikhomirov, Oleg ^b   Chen, Lianyi ^b   Lee, Hye Jeong ^a   Yull, Fiona ^b,c   Khabele, Dineo ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Bioluminescence; Macrophages; NF B activity; Ovarian cancer; Syngeneic mouse model

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MANNOSE RECEPTOR; MESSENGER RNA; SYNAPTOTAGMIN I; THYMOQUINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES FLUID; BIOLUMINESCENCE; C57BL 6 MOUSE; CANCER GROWTH; CONTROLLED STUDY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM LAVAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSGENE; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84883878485     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-63     Document Type: Article

References (40)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 11 30 10.3322/caac.21166 23335087
2. The biology of ovarian cancer: new opportunities for translation. Bast RC Jr, Hennessy B, Mills GB, Nat Rev Cancer 2009 9 415 428 10.1038/nrc2644 19461667
3. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Hanahan D, Coussens LM, Cancer Cell 2012 21 309 322 10.1016/j.ccr.2012.02.022 22439926
4. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR, J Exp Med 2008 205 1261 1268 10.1084/jem.20080108 18490490
5. Early events in the pathogenesis of epithelial ovarian cancer. Landen CN Jr, Birrer MJ, Sood AK, J Clin Oncol 2008 26 995 1005 10.1200/JCO.2006.07.9970 18195328
6. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Balkwill F, Charles KA, Mantovani A, Cancer Cell 2005 7 211 217 10.1016/j.ccr.2005.02.013 15766659
7. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR, J Immunol 2005 175 1197 1205 16002723
8. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL, Cancer Res 2005 65 10355 10362 10.1158/0008-5472.CAN- 05-0957 16288025
9. Inflammation and cancer. Coussens LM, Werb Z, Nature 2002 420 860 867 10.1038/nature01322 12490959
10. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F, Cancer Res 2007 67 585 592 10.1158/0008-5472.CAN-06-2941 17234767
11. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM, Drew AF, Cancer Res 2007 67 5708 5716 10.1158/0008-5472.CAN-06-4375 17575137
12. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM, Cancer Res 2010 70 4005 4014 10.1158/0008-5472.CAN-09-3912 20424119
13. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T, Nature 2009 462 104 107 10.1038/nature08462 19847165
14. The IkappaB kinase-a bridge between inflammation and cancer. Karin M, Cell Res 2008 18 334 342 10.1038/cr.2008.30 18301380
15. Cancer: an inflammatory link. Balkwill F, Coussens LM, Nature 2004 431 405 406 10.1038/431405a 15385993
16. Nuclear factor-kappaB: the enemy within. Aggarwal BB, Cancer Cell 2004 6 203 208 10.1016/j.ccr.2004.09.003 15380510
17. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Bonizzi G, Karin M, Trends Immunol 2004 25 280 288 10.1016/j.it.2004.03.008 15145317
18. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Son DS, Parl AK, Rice VM, Khabele D, Cancer Biol Ther 2007 6 1302 1312 17712227
19. Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Sethi G, Ahn KS, Aggarwal BB, Mol Cancer Res 2008 6 1059 1070 10.1158/1541-7786.MCR-07-2088 18567808
20. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR, J Immunol 2006 176 5023 5032 16585599
21. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Coussens LM, Zitvogel L, Palucka AK, Science 2013 339 286 291 10.1126/science.1232227 23329041
22. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G, Am J Reprod Immunol 2012 67 256 265 10.1111/j.1600-0897.2011.01068.x 21917055
23. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL, J Immunol 2011 186 6905 6913 10.4049/jimmunol.1100274 21551365
24. Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. Mhawech-Fauceglia P, Wang D, Ali L, Lele S, Huba MA, Liu S, Odunsi K, Cancer Immun 2013 13 1 23390372
25. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, Sadikot RT, Christman JW, Yull FE, Blackwell TS, J Immunol 2006 176 4995 5005 16585596
26. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, Fingleton B, Mol Cancer Res 2008 6 364 371 10.1158/1541-7786.MCR-07-0309 18337446
27. Development of a syngeneic mouse model for events related to ovarian cancer. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF, Carcinogenesis 2000 21 585 591 10.1093/carcin/21.4. 585 10753190
28. Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax. Roby KF, Niu F, Rajewski RA, Decedue C, Subramaniam B, Terranova PF, Adv Exp Med Biol 2008 622 169 181 10.1007/978-0-387-68969-2-14 18546627
29. Myeloid cells control termination of lung inflammation through the NF-kappaB pathway. Han W, Joo M, Everhart MB, Christman JW, Yull FE, Blackwell TS, Am J Physiol Lung Cell Mol Physiol 2009 296 320 L327 10.1152/ajplung.90485. 2008 19098124
30. Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Lei X, Lv X, Meng L, Yang Z, Ji M, Guo X, Dong W, Biochem Biophys Res Comm 2012 417 864 868 10.1016/j.bbrc.2011.12.063 22206670
31. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609
32. An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA, Int J Clin Exp Pathol 2012 5 37 45 22295145
33. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM, Cancer Biol Ther 2007 6 795 801 10.4161/cbt.6.5.4007 17387270
34. HDAC4 promotes growth of colon cancer cells via repression of p21. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, Mariadason JM, Mol Biol Cell 2008 19 4062 4075 10.1091/mbc.E08-02-0139 18632985
35. The peritoneal tumour microenvironment of high-grade serous ovarian cancer. Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S, Balkwill FR, J Pathol 2012 227 136 145 10.1002/path.4002 22322968
36. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS, Am J Surg Pathol 2010 34 627 635 20414098
37. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. MacCallum DE, Hall PA, J Pathol 2000 190 537 544 10.1002/(SICI)1096- 9896(200004)190:5<537::AID-PATH577>3.0.CO;2-W 10727979
38. NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model. Connelly L, Barham W, Onishko HM, Chen L, Sherrill TP, Zabuawala T, Ostrowski MC, Blackwell TS, Yull FE, Breast Cancer Res 2011 13 83 10.1186/bcr2935 21884585
39. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y, Nature 2004 431 461 466 10.1038/nature02924 15329734
40. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Basseres DS, Baldwin AS, Oncogene 2006 25 6817 6830 10.1038/sj.onc.1209942 17072330